Mechanisms of bone destruction in multiple myeloma

Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth

(2017) J Delgado-Calle et al.   LEUKEMIA

EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma–Induced Epigenetic Suppression of Osteoblast Differentiation

(2017) Juraj Adamik et al.   MOLECULAR CANCER RESEARCH

Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma

(2016) Ailing Lu et al.   AMERICAN JOURNAL OF PATHOLOGY

The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors

(2015) Denise Toscani et al.   JOURNAL OF BONE AND MINERAL RESEARCH

A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events

(2014) Swaminathan P. Iyer et al.   BRITISH JOURNAL OF HAEMATOLOGY

Sotatercept in patients with osteolytic lesions of multiple myeloma

(2014) Kudrat M. Abdulkadyrov et al.   BRITISH JOURNAL OF HAEMATOLOGY

Oncogenic roles of EMT-inducing transcription factors

(2014) Alain Puisieux et al.   NATURE CELL BIOLOGY

Romosozumab in Postmenopausal Women with Low Bone Mineral Density

(2014) Michael R. McClung et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of bone disease in multiple myeloma

(2014) Evangelos Terpos et al.   Expert Review of Hematology

Apoptotic Osteocytes and the Control of Targeted Bone Resorption

(2014) Lilian I. Plotkin   Current Osteoporosis Reports

Osteoblastic Wnts differentially regulate bone remodeling and the maintenance of bone marrow mesenchymal stem cells

(2013) Yong Wan et al.   BONE

Osteocyte-Driven Bone Remodeling

(2013) Teresita Bellido   CALCIFIED TISSUE INTERNATIONAL

The effects of bortezomib on bone disease in patients with multiple myeloma

(2013) Mohamad Mohty et al.   CANCER

Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin

(2013) Joachim Albers et al.   JOURNAL OF CELL BIOLOGY

Down-Regulation of Canonical and Up-Regulation of Non-Canonical Wnt Signalling in the Carcinogenic Process of Squamous Cell Lung Carcinoma

(2013) Domokos Bartis et al.   PLoS One

Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy

(2012) E. Terpos et al.   ANNALS OF ONCOLOGY

Metastatic myeloma?

(2012) K. Shain   BLOOD

Developmental Stage and Time Dictate the Fate of Wnt/β-Catenin-Responsive Stem Cells in the Mammary Gland

(2012) Renée van Amerongen et al.   Cell Stem Cell

Osteocyte RANKL: New insights into the control of bone remodeling

(2012) Jinhu Xiong et al.   JOURNAL OF BONE AND MINERAL RESEARCH

VEGF, FLT3 ligand, PlGF and HGF can substitute for M-CSF to induce human osteoclast formation: implications for giant cell tumour pathobiology

(2012) Richard M Taylor et al.   LABORATORY INVESTIGATION

Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation

(2012) N Giuliani et al.   LEUKEMIA

Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease

(2011) S. D'Souza et al.   BLOOD

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy

(2011) Evangelos Terpos et al.   INTERNATIONAL JOURNAL OF CANCER

Myeloma cells suppress osteoblasts through sclerostin secretion

(2011) S Colucci et al.   Blood Cancer Journal

Sclerostin: Current Knowledge and Future Perspectives

(2010) M. J. C. Moester et al.   CALCIFIED TISSUE INTERNATIONAL

CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth

(2010) Katia Beider et al.   EXPERIMENTAL HEMATOLOGY

Receptor Activator of NF-κB (RANK) Cytoplasmic IVVY535–538Motif Plays an Essential Role in Tumor Necrosis Factor-α (TNF)-mediated Osteoclastogenesis

(2010) Joel Jules et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The amazing osteocyte

(2010) Lynda F Bonewald   JOURNAL OF BONE AND MINERAL RESEARCH

TGF-β Inhibition Restores Terminal Osteoblast Differentiation to Suppress Myeloma Growth

(2010) Kyoko Takeuchi et al.   PLoS One

A High-Affinity Fully Human Anti-IL-6 mAb, 1339, for the Treatment of Multiple Myeloma

(2009) M. Fulciniti et al.   CLINICAL CANCER RESEARCH

Dickkopf-1: a suitable target for the management of myeloma bone disease

(2009) Maria Gavriatopoulou et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Pathogenesis and management of myeloma bone disease

(2009) Dimitrios Christoulas et al.   Expert Review of Hematology

Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma

(2008) Y.-W. Qiang et al.   BLOOD

Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma

(2008) Martin Kaiser et al.   EUROPEAN JOURNAL OF HAEMATOLOGY